z-logo
open-access-imgOpen Access
Clinical history and management recommendations of the smooth muscle dysfunction syndrome due to ACTA2 arginine 179 alterations
Author(s) -
Ellen S. Regalado,
Lauren Mellor-Crummey,
Julie De Backer,
Alan C. Braverman,
Lesley C. Adès,
Susan Benedict,
Timothy J. Bradley,
M. Elizabeth Brickner,
Kathryn C. Chatfield,
Anne H. Child,
Cori Feist,
Kathryn W. Holmes,
Glen Iannucci,
Birgit Lorenz,
Paul R. Mark,
Takayuki Morisaki,
Hiroko Morisaki,
Shaine A. Morris,
Anna L. Mitchell,
John R. Østergaard,
Julie Richer,
Denver Sallee,
Sherene Shalhub,
Mustafa Tekin,
Anthony L. Estrera,
Patricia Musolino,
Anji T. Yetman,
Reed E. Pyeritz,
Dianna M. Milewicz
Publication year - 2018
Publication title -
genetics in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.509
H-Index - 128
eISSN - 1530-0366
pISSN - 1098-3600
DOI - 10.1038/gim.2017.245
Subject(s) - medicine , ductus arteriosus , cardiology , aortic dissection , aneurysm , stroke (engine) , stenosis , thoracic aortic aneurysm , aortic aneurysm , surgery , aorta , mechanical engineering , engineering
Smooth muscle dysfunction syndrome (SMDS) due to heterozygous ACTA2 arginine 179 alterations is characterized by patent ductus arteriosus, vasculopathy (aneurysm and occlusive lesions), pulmonary arterial hypertension, and other complications in smooth muscle-dependent organs. We sought to define the clinical history of SMDS to develop recommendations for evaluation and management.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom